Molecular epidemiologic analysis of hepatitis C virus infection in injecting drug users with acute hepatitis C in Japan

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue 11, 2004, Pages 1305-1311

  Satoh, Yasuhiro ^a   Hino, Keisuke ^a   Kato, Takanobu ^b   Mizokami, Masashi ^b   Yamashita, Satoyoshi ^c   Nakamura, Hiroki ^a,d   Okita, Kiwamu ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c Shimonoseki Kohsei Hospital   (Japan)

^d Hagi Civil Hospital   (Japan)

Author keywords

Chronic hepatitis C; Hepatitis C virus E2 gene; Phylogenetic analysis

Indexed keywords

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTRAVENOUS DRUG ABUSE; JAPAN; MALE; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PRIORITY JOURNAL; VIRUS GENE; VIRUS TRANSMISSION; VIRUS TYPING;

EID: 8344260662     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03444.x     Document Type: Article

References (27)

1. Thomas DL. Hepatitis C epidemiology: injecting new tools in the field [Editorial; comment]. Hepatology 2000; 31: 790-1.
2. Japanese Red Cross Non-A, Non-B hepatitis research group. Effect of screening for hepatitis C virus antibody and hepatitis B virus core antibody on incidence of post-transfusion hepatitis. Lancet 1991; 338: 1040-1.
3. Crofits N, Jolly D, van Kaldor JBI, Wodak A. Epidemiology of hepatitis C virus infection among injecting drug users in Australia. J. Epidemiol. Community Health 1997; 51: 692-7.
4. Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 2001; 34: 180-7.
5. Miller CI, Johnston C, Spittal PM et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002; 36: 737-42.
6. Hahn JA, Page-Shafer K, Lum PJ et al. Hepatitis C virus seroconversion among young injection drug users: relationship and risks. J. Infect. Dis. 2002; 186: 1558-64.
7. Van Ameijden EJ, Langendam MW, Notenboom J, Goutinho RA. Continuing injecting risk behaviour: results from the Amsterdam cohort study of drug users. Addiction 1999; 94: 1051-61.
8. Galeazzi B, Tufano A, Barbierato E, Bortrolotti F. Hepatitis C virus infection in Italian intravenous drug users: epidemiological and clinical aspects. Liver 1995; 15: 209-12.
9. Alter HJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 1999; 341: 556-62.
10. Pawlotsky JM, Tsakiris L, Roudot-Thoraval F et al. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J. Infect. Dis. 1995; 171: 1607-10.
11. Watson JP, Brind AM, Chapman CE et al. Hepatitis C virus: epidemiology and genotypes in the north east of England. Gut 1996; 38: 269-76.
12. Trepo C, Pradat P. Hepatitis C virus infection in Western Europe. J. Hepatol. 1999; 31: 80-3.
13. Molin GD, Ansaldi F, Biagi C et al. Changing molecular epidemiology of hepatitis C virus infection in Northeast Italy. J. Med. Virol. 2002; 68: 352-6.
14. Cochrane A, Searle B, Hardie A et al. A genetic analysis of hepatitis C virus transmission between injection drug users. J. Infect. Dis. 2002; 186: 1212-21.
15. Krekulova L, Rehak V, Madrigal N, Johnson M, Killoran P, Riley LW. Genotypic and epidemiologic characteristics of hepatitis C virus infections among recent injection drug user and nonuser populations. Clin. Infect. Dis. 2001; 33: 1435-8.
16. Kalinina O, Norder H, Vetrov T et al. Shift in predominating subtype of HCV from 1b to 3a in St. Petersburg mediated by increase in injecting drug use. J. Med. Virol. 2001; 65: 517-24.
17. Naoumov NV. Hepatitis C virus infection in Eastern Europe. J. Hepatol. 1999; 31: 84-7.
18. Moriya T, Koyama T, Tanaka J, Mishiro S, Yoshizawa H. Epidemiology of hepatitis C virus in Japan. Intervirology 1999; 42: 153-8.
19. Hino K, Okuda M, Korenaga M et al. Clinical evaluation of chronic liver diseases induced by different hepatitis C virus genotypes in Japan, focused on the difference between genotype III/2a and IV/2b. Hepatol. Res. 1999; 14:204-11.
20. Okamoto H, Sugiyama Y, Okada S et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J. Gen. Virol. 1992; 73: 673-9.
21. Hino K, Okuda M, Konishi T, Ishiko H, Okita K. Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-α therapy. Dig. Dis. Sci. 1995; 40: 14-20.
22. Simmonds P, Alberti A, Alter HJ et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-4.
23. Okuda M, Hino K, Korenaga M, Yamaguchi Y, Katoh Y, Okita K. Differences in hypervariable region 1 quasispecies of hepatitis C virus in human serum, peripheral blood mononuclear cells, and liver. Hepatology 1999; 29: 217-22.
24. Gojobori T, Ishii K, Nei M. Estimation of average number of nucleotide substitutions when the rate of substitution varies with nucleotide. J. Mol. Evol. 1982; 18: 414-23.
25. Ina Y. ODEN. A program package for molecular evolutionary analysis and database search of DNA and amino acid sequences. CABIO 1994; 10: 11-12.
26. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 1987; 4: 406-25.
27. Tanaka Y, Hanada K, Mizokami M et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc. Natl Acad. Sci. USA 2002; 99: 15584-9.